Tag: Silo Pharma - Page 5 - Psychedelic Alpha

Read more about the article Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Post published:July 12, 2021
Post category:Press Release

Read more about the article Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Post published:June 8, 2021
Post category:Press Release

Read more about the article Silo Pharma Submits Application for NASDAQ up-listing

Silo Pharma Submits Application for NASDAQ up-listing

Post published:May 25, 2021
Post category:Press Release

Read more about the article Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Post published:May 13, 2021
Post category:Press Release

Read more about the article Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Post published:April 28, 2021
Post category:Press Release

Read more about the article Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Post published:April 22, 2021
Post category:Press Release

Read more about the article Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Post published:April 7, 2021
Post category:Press Release

Read more about the article Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Post published:March 4, 2021
Post category:Press Release

Read more about the article Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Post published:February 18, 2021
Post category:Press Release

Read more about the article Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Post published:February 10, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.